143 related articles for article (PubMed ID: 37199427)
1. Bone and Renal Health in Infants With or Without Breastmilk Exposure to Tenofovir-Based Maternal Antiretroviral Treatment in the PROMISE Randomized Trial.
Vhembo T; Baltrusaitis K; Tierney C; Owor M; Dadabhai S; Violari A; Theron G; Moodley D; Mukwasi-Kahari C; George K; Shepherd J; Siberry GK; Browning R; Fowler MG; Stranix-Chibanda L;
J Acquir Immune Defic Syndr; 2023 Aug; 93(5):431-437. PubMed ID: 37199427
[TBL] [Abstract][Full Text] [Related]
2. Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial.
Stranix-Chibanda L; Tierney C; Pinilla M; George K; Aizire J; Chipoka G; Mallewa M; Naidoo M; Nematadzira T; Kusakara B; Violari A; Mbengeranwa T; Njau B; Fairlie L; Theron G; Mubiana-Mbewe M; Khadse S; Browning R; Fowler MG; Siberry GK;
PLoS One; 2021; 16(8):e0255250. PubMed ID: 34415933
[TBL] [Abstract][Full Text] [Related]
3. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Stranix-Chibanda L; Tierney C; Sebikari D; Aizire J; Dadabhai S; Zanga A; Mukwasi-Kahari C; Vhembo T; Violari A; Theron G; Moodley D; George K; Fan B; Sommer MJ; Browning R; Mofenson LM; Shepherd J; Nelson B; Fowler MG; Siberry GK;
PLoS One; 2021; 16(2):e0246272. PubMed ID: 33544759
[TBL] [Abstract][Full Text] [Related]
4. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
Baltrusaitis K; Makanani B; Tierney C; Fowler MG; Moodley D; Theron G; Nyakudya LH; Tomu M; Fairlie L; George K; Heckman B; Knowles K; Browning R; Siberry GK; Taha TE; Stranix-Chibanda L;
BMC Infect Dis; 2022 Jul; 22(1):634. PubMed ID: 35858874
[TBL] [Abstract][Full Text] [Related]
5. Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial.
Flynn PM; Taha TE; Cababasay M; Fowler MG; Mofenson LM; Owor M; Fiscus S; Stranix-Chibanda L; Coutsoudis A; Gnanashanmugam D; Chakhtoura N; McCarthy K; Mukuzunga C; Makanani B; Moodley D; Nematadzira T; Kusakara B; Patil S; Vhembo T; Bobat R; Mmbaga BT; Masenya M; Nyati M; Theron G; Mulenga H; Butler K; Shapiro DE;
J Acquir Immune Defic Syndr; 2018 Apr; 77(4):383-392. PubMed ID: 29239901
[TBL] [Abstract][Full Text] [Related]
6. Effect of HIV infection on growth and bone density in peripubertal children in the era of antiretroviral therapy: a cross-sectional study in Zimbabwe.
Rukuni R; Rehman AM; Mukwasi-Kahari C; Madanhire T; Kowo-Nyakoko F; McHugh G; Filteau S; Chipanga J; Simms V; Mujuru H; Ward KA; Ferrand RA; Gregson CL
Lancet Child Adolesc Health; 2021 Aug; 5(8):569-581. PubMed ID: 34139202
[TBL] [Abstract][Full Text] [Related]
7. Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component.
Flynn PM; Taha TE; Cababasay M; Butler K; Fowler MG; Mofenson LM; Owor M; Fiscus S; Stranix-Chibanda L; Coutsoudis A; Gnanashanmugam D; Chakhtoura N; McCarthy K; Frenkel L; Beck I; Mukuzunga C; Makanani B; Moodley D; Nematadzira T; Kusakara B; Patil S; Vhembo T; Bobat R; Mmbaga BT; Masenya M; Nyati M; Theron G; Mulenga H; Shapiro DE;
J Acquir Immune Defic Syndr; 2021 Oct; 88(2):206-213. PubMed ID: 34108383
[TBL] [Abstract][Full Text] [Related]
8. Self-reported Antiretroviral Adherence: Association With Maternal Viral Load Suppression in Postpartum Women Living With HIV-1 From Promoting Maternal and Infant Survival Everywhere, a Randomized Controlled Trial in Sub-Saharan Africa and India.
Nevrekar N; Butler K; Shapiro DE; Atuhaire P; Taha TE; Makanani B; Chinula L; Owor M; Moodley D; Chipato T; McCarthy K; Flynn PM; Currier J; Fowler MG; Gupta A; Suryavanshi N
J Acquir Immune Defic Syndr; 2023 Jan; 92(1):76-83. PubMed ID: 36170749
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Bernardino JI; Mocroft A; Mallon PW; Wallet C; Gerstoft J; Russell C; Reiss P; Katlama C; De Wit S; Richert L; Babiker A; Buño A; Castagna A; Girard PM; Chene G; Raffi F; Arribas JR;
Lancet HIV; 2015 Nov; 2(11):e464-73. PubMed ID: 26520926
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
11. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
Siberry GK; Jacobson DL; Kalkwarf HJ; Wu JW; DiMeglio LA; Yogev R; Knapp KM; Wheeler JJ; Butler L; Hazra R; Miller TL; Seage GR; Van Dyke RB; Barr E; Davtyan M; Mofenson LM; Rich KC;
Clin Infect Dis; 2015 Sep; 61(6):996-1003. PubMed ID: 26060285
[TBL] [Abstract][Full Text] [Related]
12. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.
Jamieson DJ; Chasela CS; Hudgens MG; King CC; Kourtis AP; Kayira D; Hosseinipour MC; Kamwendo DD; Ellington SR; Wiener JB; Fiscus SA; Tegha G; Mofolo IA; Sichali DS; Adair LS; Knight RJ; Martinson F; Kacheche Z; Soko A; Hoffman I; van der Horst C;
Lancet; 2012 Jun; 379(9835):2449-2458. PubMed ID: 22541418
[TBL] [Abstract][Full Text] [Related]
13. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
14. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
[TBL] [Abstract][Full Text] [Related]
15. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
16. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
Mirembe BG; Kelly CW; Mgodi N; Greenspan S; Dai JY; Mayo A; Piper J; Akello CA; Kiweewa FM; Magure T; Nakabiito C; Marrazzo JM; Chirenje ZM; Riddler SA;
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):287-94. PubMed ID: 26866954
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
18. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
Fowler MG; Qin M; Fiscus SA; Currier JS; Flynn PM; Chipato T; McIntyre J; Gnanashanmugam D; Siberry GK; Coletti AS; Taha TE; Klingman KL; Martinson FE; Owor M; Violari A; Moodley D; Theron GB; Bhosale R; Bobat R; Chi BH; Strehlau R; Mlay P; Loftis AJ; Browning R; Fenton T; Purdue L; Basar M; Shapiro DE; Mofenson LM;
N Engl J Med; 2016 Nov; 375(18):1726-1737. PubMed ID: 27806243
[TBL] [Abstract][Full Text] [Related]
19. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
Solomon MM; Lama JR; Glidden DV; Mulligan K; McMahan V; Liu AY; Guanira JV; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Burns DN; Grant RM;
AIDS; 2014 Mar; 28(6):851-9. PubMed ID: 24499951
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
